Repare Therapeutics | 10-Q: FY2025 Q2 Revenue: USD 250 K

LB filings
2025.08.08 11:17
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q2, the actual value is USD 250 K.

EPS: As of FY2025 Q2, the actual value is USD -0.39, beating the estimate of USD -0.56.

Segment Revenue

  • Collaboration Agreements: Revenue from collaboration agreements was $250,000 for the three months ended June 30, 2025, compared to $1,073,000 for the same period in 2024. For the six months ended June 30, 2025, revenue was $250,000 compared to $53,477,000 for the same period in 2024.

Operational Metrics

  • Research and Development Expenses: Research and development expenses were $14,283,000 for the three months ended June 30, 2025, compared to $30,075,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $34,553,000 compared to $63,045,000 for the same period in 2024.
  • General and Administrative Expenses: General and administrative expenses were $6,029,000 for the three months ended June 30, 2025, compared to $8,317,000 for the same period in 2024. For the six months ended June 30, 2025, expenses were $13,681,000 compared to $16,935,000 for the same period in 2024.
  • Restructuring Expenses: Restructuring expenses were $3,384,000 for the three months ended June 30, 2025, and $6,649,000 for the six months ended June 30, 2025. There were no restructuring expenses for the same periods in 2024.
  • Net Loss: Net loss was $16,744,000 for the three months ended June 30, 2025, compared to $34,774,000 for the same period in 2024. For the six months ended June 30, 2025, net loss was $46,787,000 compared to $21,612,000 for the same period in 2024.

Cash Flow

  • Operating Cash Flow: Net cash used in operating activities was $45,475,000 for the six months ended June 30, 2025, compared to $18,582,000 for the same period in 2024.
  • Investing Cash Flow: Net cash provided by investing activities was $28,206,000 for the six months ended June 30, 2025, compared to net cash used in investing activities of $13,198,000 for the same period in 2024.
  • Financing Cash Flow: Net cash provided by financing activities was $79,000 for the six months ended June 30, 2025, compared to $375,000 for the same period in 2024.

Unique Metrics

  • Gain on Sale of Technology and Other Assets: The company recognized a gain of $5,666,000 on the sale of technology and other assets for the three and six months ended June 30, 2025.

Future Outlook and Strategy

  • Core Business Focus: The company is focusing on the continued advancement of its Phase 1 clinical programs, RP-3467 and RP-1664. Expected milestones include topline safety, tolerability, and early efficacy data from the POLAR trial in Q4-2025 and initial topline safety, tolerability, and early efficacy data from the LIONS trial in Q4-2025.
  • Non-Core Business: The company has out-licensed its early-stage discovery platforms to DCx Biotherapeutics Corporation and entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib. These transactions are expected to provide near-term payments and potential future milestone payments and royalties.
  • Priority: The company is actively exploring strategic alternatives, partnerships, and sale opportunities across its portfolio to maximize shareholder value.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.